Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Market Cap	33.24B
Revenue (ttm)	3.14B
Net Income (ttm)	951.15M
Shares Out	406.80M
EPS (ttm)	2.33
PE Ratio	35.09
Forward PE	25.87
Dividend	0.62 (0.76%)
Ex-Dividend Date	May 9, 2025

Volume	2,303,778
Average Volume	3,122,441
Open	83.10
Previous Close	82.99
Day's Range	81.70 - 83.87
52-Week Range	57.28 - 93.52
Beta	-0.28
RSI	45.26
Earnings Date	Aug 21, 2025

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 2,423
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688278

Financial Performance

In 2024, Xiamen Amoytop Biotech's revenue was 2.82 billion, an increase of 34.13% compared to the previous year's 2.10 billion. Earnings were 827.60 million, an increase of 49.00%.